What is the difference between Vumerity and Mayzent?
Vumerity (diroximel fumarate) and Mayzent (siponimod) are both oral medications approved for the treatment of relapsing forms of multiple sclerosis (MS). While they share a common therapeutic goal, they belong to different drug classes and have distinct mechanisms of action and regulatory histories.
How do Vumerity and Mayzent work?
Vumerity is an fumaric acid ester. It is believed to work by modulating the immune system, reducing inflammation that contributes to MS disease activity. It is a prodrug that is rapidly converted in the body to monomethyl fumarate (MMF), the active metabolite. MMF is thought to activate the Nrf2 antioxidant pathway, which can reduce oxidative stress and inflammation [1].
Mayzent is a sphingosine-1-phosphate (S1P) receptor modulator. It works by binding to S1P receptors on lymphocytes, trapping them in the lymph nodes. This reduces the number of lymphocytes that can migrate to the central nervous system (CNS), thereby decreasing inflammation and neurodegeneration associated with MS [2].
What are the approved uses for Vumerity and Mayzent?
Vumerity is approved for the treatment of relapsing forms of multiple sclerosis in adults [1].
Mayzent is approved for the treatment of relapsing forms of multiple sclerosis in adults [2]. It is also indicated for active secondary progressive multiple sclerosis in adults [2].
What are the clinical trial results for these MS drugs?
In clinical trials, Vumerity demonstrated a reduction in annualized relapse rates compared to placebo. It also showed a reduction in the number of T1 gadolinium-enhancing lesions and new or newly enlarging T2 lesions on MRI [1].
Mayzent also demonstrated a reduction in annualized relapse rates and a slowing of disability progression in clinical trials, as measured by the time to 3-month confirmed disability progression [2].
What are the side effects associated with Vumerity and Mayzent?
Common side effects for Vumerity include flushing, gastrointestinal events (nausea, diarrhea, abdominal pain), and liver enzyme elevations [1].
Common side effects for Mayzent include infections (upper respiratory tract infection, herpes zoster), headache, dizziness, and hair thinning [2]. Mayzent also carries a risk of bradycardia, macular edema, and elevated liver enzymes [2].
What is the patent status for Vumerity and Mayzent?
Information on the patent status of Vumerity and Mayzent can be found on DrugPatentWatch.com [3]. These resources provide details on patent expiry dates, patent litigation, and the potential for generic or biosimilar competition.
How do Vumerity and Mayzent compare in terms of efficacy and safety?
Direct head-to-head comparative trials between Vumerity and Mayzent are limited. Efficacy and safety profiles are assessed based on individual clinical trial data. Vumerity is generally considered to have a favorable gastrointestinal tolerability profile compared to its predecessor, dimethyl fumarate. Mayzent, as an S1P receptor modulator, offers a different mechanism and may be considered for patients with active secondary progressive MS, a distinct indication from Vumerity's current approval. The choice between the two medications depends on individual patient factors, including disease activity, disease subtype, comorbidities, and tolerability [1, 2].
---
Sources
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/